ES2134860T3 - Preparacion farmaceutica de accion prolongada. - Google Patents

Preparacion farmaceutica de accion prolongada.

Info

Publication number
ES2134860T3
ES2134860T3 ES93924826T ES93924826T ES2134860T3 ES 2134860 T3 ES2134860 T3 ES 2134860T3 ES 93924826 T ES93924826 T ES 93924826T ES 93924826 T ES93924826 T ES 93924826T ES 2134860 T3 ES2134860 T3 ES 2134860T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
tetrone
azatricyclo
methoxycyclohexyl
octa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93924826T
Other languages
English (en)
Inventor
Akira Kagayama
Sumihisa Kimura
Saburo Murata
Sachiyo Tanimoto
Takehisa Hata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2134860T3 publication Critical patent/ES2134860T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA PREPARACION FARMACEUTICA DE ACCION PROLONGADA QUE COMPRENDE UN COMPUESTO MACROCICLICO REPRESENTADO POR 17-ALQUIL- 1,14- DIHIDROXI12-[2-( 4-HIDROXI- 3 - METOXICICLOHEXIL) - 1- METILVINIL] - 23, 25 -DIMETOXI - 13,19,21,27- TETRAMETIL- 11,28-DIOXA 4-AZOTRICICLO[22.3.1.04.9]OCTA - COS -18-ENO- 2,3,10,16-TETRONA O 17-ETIL-1,14-DIHIDROXI- 12-[4-HIDROXI- 3- METOXICICLOHEXILO)-1 -METILVINIL]- 23,25-DIMETOXI- 13,19,21,27- TETRAMETIL- 11,28DIOXA-4-AZOTRICICLO[22.3.1.04.9] OCTA - COS -18-ENO2,3,10,16-TETRONA ENCERRADO EN UNA, ASI LLAMADA, MICROESFERA, P. EJ., UNA PARTICULA FINA DE UNA SUBSTANCIA MACROMOLECULAR BIODEGRADABLE. CUANDO ESTA PREPARACION ES ADMINISTRADA EN LA FORMA DE UNA SOLUCION PARENTAL, EL COMPUESTO MACROLICO PUEDE MIGRAR MUY BIEN EN LA SANGRE. ADICIONALMENTE ES ADECUADO PARA ADMINISTRACION TOPICA.
ES93924826T 1992-11-18 1993-11-11 Preparacion farmaceutica de accion prolongada. Expired - Lifetime ES2134860T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30888592 1992-11-18

Publications (1)

Publication Number Publication Date
ES2134860T3 true ES2134860T3 (es) 1999-10-16

Family

ID=17986438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93924826T Expired - Lifetime ES2134860T3 (es) 1992-11-18 1993-11-11 Preparacion farmaceutica de accion prolongada.

Country Status (11)

Country Link
US (1) US5601844A (es)
EP (1) EP0669127B1 (es)
JP (1) JP3520517B2 (es)
CN (1) CN1093571A (es)
AT (1) ATE183083T1 (es)
AU (1) AU5434094A (es)
DE (1) DE69326015T2 (es)
DK (1) DK0669127T3 (es)
ES (1) ES2134860T3 (es)
GR (1) GR3031179T3 (es)
WO (1) WO1994010981A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
WO1997010806A1 (en) 1995-09-19 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Aerosol compositions
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
US6127520A (en) * 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
ATE268212T1 (de) 1998-03-16 2004-06-15 Nalco Co Bei recycling von behandelten behältern nützliche verunreinigungs-dispergierungsmittel
US6113738A (en) * 1998-03-16 2000-09-05 Nalco Chemical Company Use of additives to breakdown and stabilize wax during fiber recycle
DK2198858T3 (da) * 1998-03-26 2011-10-03 Astellas Pharma Inc Præparat med opretholdt frigivelse af en makrolidforbindelse såsom tacrolimus
AU6047099A (en) 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
CN1859909B (zh) * 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
DK2575769T3 (en) 2010-02-17 2016-09-26 Veloxis Pharmaceuticals As stabilized tacrolismussammensætning
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
DE3853477T2 (de) * 1987-12-09 1995-11-09 Fisons Plc Makrozyklische verbindungen.
US5196437A (en) * 1990-02-13 1993-03-23 Fujisawa Pharmaceutical Company, Ltd. Method for treating hepatic diseases and regenerating liver tissue using FK 506 and related compounds
CA2012978C (en) * 1990-02-13 2002-02-26 Thomas E. Starzl Treatment of hepatic diseases using fk 506 and related compounds
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
JPH0449232A (ja) * 1990-06-15 1992-02-18 Fujisawa Pharmaceut Co Ltd 懸濁用組成物または懸濁液並びにそれらの製造法
DK0474126T3 (es) * 1990-09-04 1997-04-07 Fujisawa Pharmaceutical Co
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same

Also Published As

Publication number Publication date
EP0669127B1 (en) 1999-08-11
GR3031179T3 (en) 1999-12-31
DK0669127T3 (da) 1999-12-06
JP3520517B2 (ja) 2004-04-19
US5601844A (en) 1997-02-11
DE69326015T2 (de) 2000-02-03
EP0669127A1 (en) 1995-08-30
DE69326015D1 (de) 1999-09-16
AU5434094A (en) 1994-06-08
EP0669127A4 (en) 1995-11-02
CN1093571A (zh) 1994-10-19
ATE183083T1 (de) 1999-08-15
WO1994010981A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
ES2134860T3 (es) Preparacion farmaceutica de accion prolongada.
DK0474126T3 (es)
IL100011A0 (en) Suspendible pharmaceutical composition containing a tricyclic compound and processes for the preparation thereof
IL94971A0 (en) Aqueous pharmaceutical composition containing a tricyclic compound and processes for the preparation thereof
MX9202945A (es) Composicion consistente en una dispersion solida de la sustancia fr-900506.
DE69017360D1 (de) Wässrige flüssige Arzneizubereitungen.
NZ507345A (en) Medicinal compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 669127

Country of ref document: ES